Skip to main
UTHR

United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics (UTHR) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

United Therapeutics is expanding its indications, innovating in drug delivery, and has a strong and experienced management team, leading to positive outlook for future growth. Though there are risks such as accelerated generic erosion of market share and increased competition, the company remains resilient with its positive TETON-1 and TETON-2 data, robust TETON-2 results in IPF, and a strong pipeline with multiple upcoming catalysts. This, combined with its strong business model and disciplined cost management, gives confidence in the company's potential for success and a bullish outlook.

Bears say

United Therapeutics is facing several challenges going forward including the need for more proof in the no-background-therapy subgroup to support monotherapy use, unclear positioning of nebulized Tyvaso compared to its other formulations, and low projected earnings growth compared to the industry average. These factors, along with a composite valuation methodology that yields a $600 PT, contribute to a negative outlook on UTHR's stock.

United Therapeutics (UTHR) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About United Therapeutics (UTHR) Forecast

Analysts have given United Therapeutics (UTHR) a Buy based on their latest research and market trends.

According to 11 analysts, United Therapeutics (UTHR) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $591.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $591.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

United Therapeutics (UTHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.